Abstract: Monoclonal antibodies which have binding specificity to human CETP(CETP inhibition activity) and which are useful as reagents for purification or quantification of human CETP, and as pharmaceuticals to prevent and/or treat hyperlipidemia or arteriosclerosis are provided. Furthermore, purification and quantification methods of human CETP by using the monoclonal antibodies are also provided.
Abstract: A substantially pure protein that is a member of the apoptotic Ced-3/Ice cysteine protease gene family, Mch2&agr;, and an inactive isoform of it, Mch2&bgr;, are disclosed. Isolated nucleic acid molecules that encode Mch2&agr; and Mch2&bgr;, respectively, are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with the protein or the nucleic acid molecules are disclosed. Fragments of nucleic acid molecules that encode Mch2&agr; and Mch2&bgr; having at least 10 nucleotides and oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides are disclosed. Recombinant expression vectors that comprise the nucleic acid molecule that encode Mch2&agr; or Mch2&bgr;, and host cells that comprise such recombinant vectors are disclosed. Antibodies that bind to an epitope on Mch2&agr; and/or Mch2&bgr; are disclosed. Methods of identifying inhibitors, activators and substrates of Mch2&agr; are disclosed.
Type:
Grant
Filed:
August 17, 1999
Date of Patent:
June 18, 2002
Assignee:
Thomas Jefferson University
Inventors:
Gerald Litwack, Emad S. Alnemri, Teresa Fernandez-Alnemri
Abstract: Thiol-containing peptides can be radiolabeled with fluorine-18 (F-18) by reacting a peptide comprising a free thiol group with an F-18-bound labelling reagent which also has a group that is reactive with thiols. The resulting F-18-labeled peptides may be targeted to a tissue of interest using bispecific antibodies or bispecific antibody fragments having one arm specific for the F-18-labeled peptide or a low molecular weight hapten conjugated to the F-18-labeled peptide, and another arm specific to the targeted tissue. The targeted tissue is subsequently visualized by clinical positron emission tomography.
Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
Type:
Grant
Filed:
April 28, 2000
Date of Patent:
January 29, 2002
Assignee:
Board of Regents, The University of Texas System
Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
Type:
Grant
Filed:
April 28, 2000
Date of Patent:
January 29, 2002
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention relates to arthropod epoxide hydrolase proteins; to arthropod epoxide hydrolase nucleic acid molecules, including those that encode such epoxide hydrolase proteins; to antibodies raised against such epoxide hydrolase proteins; and to other compounds that inhibit arthropod epoxide hydrolase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from hematophagous arthropod infestation.
Type:
Grant
Filed:
August 8, 2000
Date of Patent:
September 18, 2001
Assignee:
Heska Corporation
Inventors:
Nancy Wisnewski, Gary M. Silver, Katherine Callies Lo, Kevin S. Brandt